Citigroup’s Gain Therapeutics GANX Stock Holding History

Citigroup’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2	Buy	+1	New	+$2	﹤0.01%	5830
2025 Q1	–	Sell	-2,000	Closed	-$4.32K	–	5714
2024 Q4	$4.32K	Buy	+2,000	New	+$4.01K	﹤0.01%	5477
2024 Q2	–	Sell	-684	Closed	-$2.58K	–	5649
2024 Q1	$2.58K	Buy	+684	New	+$2.84K	﹤0.01%	5369

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citigroup's GANX Position: Q1 2026 in Review

Citigroup opened a new position in Gain Therapeutics (GANX) in Q1 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #5830 among its holdings. This is a return to the name: Citigroup previously reported a position in GANX as recently as Q4 2024.

Citigroup first reported a position in GANX in Q1 2024 and has held it in 3 quarters since. The position peaked at $4.32K in Q4 2024. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Citigroup held 1 share of Gain Therapeutics worth $2 as of Q1 2026.
Gain Therapeutics was a new Citigroup position in Q1 2026.
Gain Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5830 holding.
Citigroup first reported a position in Gain Therapeutics in Q1 2024 and has held it in 3 quarters since.
Citigroup's Gain Therapeutics position peaked at $4.32K in Q4 2024.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.